FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

연구/논문
연구 도서관으로 돌아가기
PubMedReview

Mitochondria-derived peptides in aging and healthspan.

Miller Brendan, Kim Su-Jeong, Kumagai Hiroshi, Yen Kelvin, Cohen Pinchas
The Journal of clinical investigation2022DOI: 10.1172/JCI158449
humaninMOTS-cSHLPs

품질 점수

7/10

참조 문헌

0

피험자

비인간

Peptide Contacts 분석

Study Design

Review papers serve a critical role in synthesizing disparate findings into a coherent narrative. For rapidly evolving fields like peptide therapeutics, reviews help researchers and practitioners identify consensus and controversy.

Our Assessment

Quality Assessment: 7/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

These findings advance our understanding of humanin, MOTS-c, SHLPs in meaningful ways.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Strong methodology makes this a valuable addition to the humanin, MOTS-c, SHLPs evidence base. The findings here should inform future clinical trial design.

주요 발견

The review discusses recent advances in the discovery of mitochondria-derived peptides (MDPs) and their role in aging and age-related diseases such as type 2 diabetes, cancer, and neurodegenerative diseases.

제한 사항

As a review paper, it does not present new experimental data but rather synthesizes existing knowledge. The understanding of MDPs is still evolving, and more research is needed to fully understand their mechanisms and clinical implications.

이 연구를 어떻게 해석해야 하는지

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Reviews are only as good as the studies they include. Check whether the review examined study quality or simply tallied results.

4

Look for discussion of publication bias — studies with negative results are less likely to be published, which can skew review conclusions.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Peptide Contacts 분석

Highlighting the emerging role of mitochondria-derived peptides (MDPs) in aging and disease could attract interest from researchers and clinicians interested in novel therapeutic targets.

humaninMOTS-cSHLPs

Unveiling Mitochondria-Derived Peptides: A New Frontier in Aging Research

Published: May 17, 2026 | Source: The Journal of clinical investigation (2022) | Category: humanin, MOTS-c, SHLPs

Overview

Recent research highlights the potential role of mitochondria-derived peptides (MDPs) in aging and age-related diseases. These small proteins, encoded by mitochondrial DNA, could offer new insights into how cellular function declines with age and open up novel therapeutic avenues for conditions like type 2 diabetes, cancer, and neurodegenerative disorders.

Study Background

Mitochondrial dysfunction is a well-known hallmark of aging, contributing to various chronic diseases. However, the role of small proteins produced by mitochondria has been largely overlooked until recently. The review paper "Mitochondria-Derived Peptides in Aging and Healthspan" synthesizes current knowledge on MDPs, which are short peptides encoded by mitochondrial DNA (mtDNA) that play crucial roles in cellular health.

What the Research Found

The study reviews eight known MDPs: humanin, MOTS-c, and six small human longevity peptides (SHLPs). These peptides have been shown to influence various physiological processes, including glucose metabolism, insulin sensitivity, and inflammation. For instance, humanin has anti-apoptotic properties that protect against neuronal cell death, while MOTS-c enhances muscle function and metabolic health.

What This Means for Peptide Users

While the research is still in its early stages, understanding MDPs could lead to new therapeutic targets for age-related diseases. Future studies might uncover more about how these peptides interact with cellular pathways and identify potential drugs that mimic or enhance their effects. However, it's important to note that clinical applications are not yet available.

Limitations and Caveats

As a review paper, this study does not present original experimental data but rather synthesizes existing knowledge. The field of MDPs is still evolving, with many unanswered questions about their mechanisms of action and clinical implications. More research is needed to establish the full potential of these peptides in therapeutic contexts.

How This Compares to Previous Research

Previous studies have focused on larger mitochondrial proteins and broader aspects of mitochondrial function in aging. The novelty here lies in highlighting the role of small, previously underexplored peptides. While some researchers might argue that more experimental evidence is needed before drawing conclusions about MDPs' clinical relevance, this review provides a comprehensive overview of current knowledge.

Our Analysis

PeptideVault's analysis suggests that while the potential of mitochondria-derived peptides (MDPs) in aging and disease is promising, further research is essential to validate their therapeutic applications. The review effectively summarizes recent advances but acknowledges significant gaps in our understanding. Future studies should focus on elucidating MDPs' mechanisms and exploring their clinical utility.

Key Takeaways

  • Emerging Role: Mitochondria-derived peptides (MDPs) are gaining recognition for their potential roles in aging and age-related diseases.
  • Mechanistic Insights: Understanding how these small peptides interact with cellular pathways could lead to novel therapeutic targets.
  • Future Directions: More research is needed to validate the clinical relevance of MDPs and explore their full therapeutic potential.

Original Source

Citation: Miller Brendan, Kim Su-Jeong, Kumagai Hiroshi et al. (2022). Mitochondria-derived peptides in aging and healthspan.. The Journal of clinical investigation. DOI: 10.1172/JCI158449

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

편집자의 주석

Peptide Contacts 연구 팀은 복잡한 발견을 피테이드 커뮤니티에게 이해하기 쉬운 언어로 작성했습니다. 항상 원문의 전체 방법론과 데이터를 참조하십시오. humanin에 대해 더 알아보기 연구 가이드.

참조 문헌

Miller Brendan, Kim Su-Jeong, Kumagai Hiroshi et al.. (2022). Mitochondria-derived peptides in aging and healthspan.. The Journal of clinical investigation. https://doi.org/10.1172/JCI158449

PubMed에서 전체 텍스트 확인하기

관련 논문

더 알아보기

이 내용은 교차 검토된 연구를 기반으로 교육 목적용으로 생성되었습니다. 이 내용은 의학적 조언으로 간주되지 않습니다. 피테이드 기반 치료법을 사용하기 전에 항상 자격 있는 의료 전문가와 상담하십시오.